Antibiotic Therapy for Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)

Duration of Antibiotic Therapy

• A 7-8 day course of antibiotic therapy is recommended for most patients with HAP/VAP who show good clinical response to therapy, including those with non-fermenting Gram-negatives, Acinetobacter spp., and MRSA infections, according to the European Respiratory Society guidelines 1
• For patients with low probability of HAP, consider stopping antibiotics after 3 days if they have a low Clinical Pulmonary Infection Score (CPIS ≤6) and no clinical deterioration within 72 hours of symptom onset, as suggested by the European Respiratory Society guidelines 1
• Extended therapy (>8 days) should be considered for patients with immunodeficiency, cystic fibrosis, complicated pneumonia, inappropriate initial empiric therapy, pan-drug-resistant (PDR) pathogens, MRSA with poor clinical response, bacteremia, P. aeruginosa or Acinetobacter species with high risk of relapse, or those on chronic corticosteroid therapy (≥14 days), based on recommendations from the European Respiratory Society and American Thoracic Society guidelines 1, 2
• Legionnaire's disease, M. pneumoniae, and C. pneumoniae infections may require 10-14 days of treatment, as suggested by the American Thoracic Society 3
• Patients chronically treated with corticosteroids may require ≥14 days of treatment 3

Treatment of Specific Pathogens

• For P. aeruginosa and Acinetobacter infections, consider longer treatment due to higher relapse rates with shorter therapy, as recommended by the American Thoracic Society guidelines 2
• P. aeruginosa and Acinetobacter infections may have higher relapse rates with shorter therapy, requiring careful monitoring, as suggested by the American Thoracic Society 2

Clinical Assessment and De-escalation

• Evaluate patients at 72-96 hours for signs of clinical improvement, including temperature normalization, reduction in tracheobronchial secretion volume and purulence, improvement in chest radiograph, normalization of white blood cell count, and improved PaO2/FiO2 ratio, as suggested by the European Respiratory Society guidelines 1
• Clinical stability should be assessed at 72 hours to determine treatment duration, including temperature normalization, reduction in tracheobronchial secretion volume, improvement in purulence of secretions, resolution on chest radiograph, normalization of white blood cell count, and improved PaO2/FiO2 ratio, as recommended by the European Respiratory Society 1
• If using aminoglycoside-containing regimens, the aminoglycoside can be stopped after 5-7 days in responding patients, based on recommendations from the American Thoracic Society guidelines 2
• Combination therapy with an aminoglycoside-containing regimen may allow for stopping the aminoglycoside after 5-7 days in responding patients, as recommended by the American Thoracic Society 2
• For patients initially on combination therapy, de-escalate to monotherapy based on culture results when possible, as recommended by the European Respiratory Society and American Thoracic Society guidelines 1, 2
• Failure to de-escalate therapy when culture results allow for targeted monotherapy is a common error, as noted by the European Respiratory Society 1
• Inadequate clinical assessment, including not performing routine bedside clinical assessment to guide treatment decisions, is another common error, as reported by the European Respiratory Society 1

Biomarker Use and Antibiotic Stewardship

• Routine measurement of serial serum procalcitonin (PCT) is not recommended to reduce antibiotic duration when the anticipated treatment is already 7-8 days, according to the European Respiratory Society guidelines 1
• Biomarker determinations (CRP, PCT, copeptin, MR-proANP) are not routinely recommended in addition to bedside clinical assessment, as stated by the European Respiratory Society guidelines 1
• Routine measurement of serial serum procalcitonin levels is not recommended to reduce antibiotic duration when the anticipated treatment is already 7-8 days, as suggested by the European Respiratory Society 1